Get the latest news, insights, and market updates on HRTX (Heron Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide partici Feb 17, 2026 - $HRTX
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
“We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year.” Preliminary Q4 and FY25 Updates: Net revenue of approximately $40.5M for the three months ended December 31. ZYNRELEF net revenue of approximately $12.5M for the three months ended Jan 10, 2026 - $HRTX
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron. “In addition to our revenue growth, we are extremely pleased wit Jan 9, 2026 - $HRTX
Heron Therapeutics (HRTX): Forecasts Signal 60.89% Annual Earnings Growth, Path to Profitability in Focus
Heron Therapeutics (HRTX) has narrowed its losses at an impressive rate of 39.8% per year over the past five years. Earnings are now forecast to grow a further 60.89% annually. The company is expected to achieve profitability within the next three years. Revenue is projected to climb 15.9% per year, which is solidly above the US market average of 10.5%. Encouragingly for investors, the current Price-To-Sales ratio sits at just 1.3x, which is well below both biotech industry and peer... Nov 5, 2025 - $HRTX
Heron Therapeutics: Q3 Earnings Snapshot
CARY, N.C. (AP) — Heron Therapeutics Inc. HRTX) on Tuesday reported a loss of $17.5 million in its third quarter. The Cary, North Carolina-based company said it had a loss of 10 cents per share. Nov 4, 2025 - $HRTX
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $HRTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple